InfiNADi NAD+

InfiNADi NAD+ – Pharmaceutical-Grade Sterile Liquid NAD+

InfiNADi NAD+ is a sterile, ready-to-use liquid formulation of nicotinamide adenine dinucleotide (NAD+) from Regenerative Medicine Co., Ltd. (ReGenMed), a company founded in Bangkok, Thailand in 2007. It is supplied as a clinic-ready vial for hospitals, clinics and physicians that offer NAD+ therapy.

Key Features

• Clinic Ready Liquid: Supplied as a sterile solution in a vial, so no powder needs to be reconstituted.
• Pharmaceutical Grade: The manufacturer states a purity of 99.99%.
• Regulatory Background: According to ReGenMed, the product was approved by the Thailand FDA in October 2021.
• Professional Supply: Distributed to medical practitioners and healthcare facilities.

Active Ingredient & Background

• Active Ingredient: Nicotinamide Adenine Dinucleotide (NAD+)

NAD+ is a coenzyme found in all living cells. It plays a central role in:

• Energy metabolism: helping mitochondria turn nutrients into ATP
• DNA repair: serving as a substrate for repair enzymes such as PARPs
• Cell signaling: supporting the activity of sirtuins, a family of proteins studied in cellular aging

Research shows that NAD+ levels fall with age. This has made NAD+ an active area of study in regenerative and longevity medicine.

Areas of Clinical Interest

Clinics commonly include NAD+ therapy in programs focused on:

• Cellular energy and fatigue support
• Healthy aging and wellness
• Metabolic health
• Physical recovery

This section describes general research on NAD+. It is not a claim of proven results for this specific product. Human clinical evidence for many NAD+ uses is still developing, and treatment decisions should be made by a qualified physician.

Product Specifications

• Brand: InfiNADi
• Manufacturer / Brand Owner: Regenerative Medicine Co., Ltd. (ReGenMed), Bangkok, Thailand
• Active Ingredient: Nicotinamide Adenine Dinucleotide (NAD+)
• Dosage Form: Sterile liquid solution in vial
• Grade: Sterile pharmaceutical grade
• Intended Use Setting: Hospitals, clinics and licensed medical practitioners

Administration

• For use only by licensed healthcare professionals in a clinical setting.
• Dose, route, dilution and infusion rate must follow the official package insert and the treating physician’s judgment.
• Do not self-administer.

Precautions

• Infusing NAD+ too quickly has been linked to discomfort such as nausea, flushing, abdominal cramping or chest tightness. The infusion rate should be controlled and the patient monitored.
• The U.S. FDA has received reports of adverse events after NAD+ injections, including chills, shaking and vomiting, linked to contaminated non-sterile ingredients. Use only sterile products intended for injection, from a verified source.
• Do not use if the vial is damaged, leaking, discolored, contains particles or is past its expiry date.
• Keep out of reach of children.

Who Should Consult a Physician First

• Pregnant or breastfeeding women (safety data are limited)
• People with a known allergy to any component of the product
• People with serious heart, liver or kidney conditions, active cancer, or those taking prescription medicines
• Children and adolescents

Storage

Store as directed on the product label and package insert. Keep away from direct sunlight and out of reach of children.

Package Contents

• InfiNADi NAD+ sterile liquid vial(s), as stated on the outer carton

Important Notice

For professional healthcare use only. This information is for general product reference. It does not replace medical advice, the official package insert or local regulations. This product is not intended to diagnose, treat, cure or prevent any disease. Results vary between individuals.